Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan Reardon

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Nature Communications|December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancerDavid Liu, Philip Abbosh, Daniel Keliher, et al.
Nature Communications|November 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trialAdrienne G Waks, Jingxin Fu, Xiangying Chu, et al.
Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
JAMA Oncology|January 25, 2019
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell TumorsSaud H AlDubayan, Louise C Pyle, Marija Gamulin, et al.
Nature Communications|June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantTarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Research|October 13, 2020
Functional Precision Medicine Identifies New Therapeutic Candidates for MedulloblastomaJessica M Rusert, Edwin F Juarez, Sebastian Brabetz, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Nature Communications|December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancerDavid Liu, Philip Abbosh, Daniel Keliher, et al.
Nature Communications|November 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trialAdrienne G Waks, Jingxin Fu, Xiangying Chu, et al.
Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
JAMA Oncology|January 25, 2019
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell TumorsSaud H AlDubayan, Louise C Pyle, Marija Gamulin, et al.
Nature Communications|June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantTarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Research|October 13, 2020
Functional Precision Medicine Identifies New Therapeutic Candidates for MedulloblastomaJessica M Rusert, Edwin F Juarez, Sebastian Brabetz, et al.
Pageof 5